Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivian Laquer

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of the American Academy of Dermatology|October 8, 2025
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativaSeth Forman, Dipak R Patel, Alexa B Kimball, et al.
Paediatric Drugs|June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Külli Kingo, Vivian Laquer, et al.
Journal of the American Academy of Dermatology|September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Külli Kingo, Vivian Laquer, et al.
Dermatology and Therapy|July 15, 2024
The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic DermatitisJennifer Soung, Vivian Laquer, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|June 15, 2018
12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinomaVivian Laquer, Ryan W Dellinger, Irene Mannering, et al.
The British Journal of Dermatology|April 28, 2022
Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitisVivian Laquer, Viviana Parra, Jean-Philippe Lacour, et al.
Dermatology and Therapy|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialNada Elbuluk, April W Armstrong, Ronald Vender, et al.
The Journal of Allergy and Clinical Immunology|November 13, 2025
Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study resultsDiamant Thaçi, Vivian Laquer, Charles Lynde, et al.
Journal of the American Academy of Dermatology|May 25, 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, et al.
International Journal of Dermatology|April 29, 2024
Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentationAndrew Alexis, James Q Del Rosso, Seth Forman, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of the American Academy of Dermatology|October 8, 2025
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativaSeth Forman, Dipak R Patel, Alexa B Kimball, et al.
Paediatric Drugs|June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Külli Kingo, Vivian Laquer, et al.
Journal of the American Academy of Dermatology|September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Külli Kingo, Vivian Laquer, et al.
Dermatology and Therapy|July 15, 2024
The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic DermatitisJennifer Soung, Vivian Laquer, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|June 15, 2018
12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinomaVivian Laquer, Ryan W Dellinger, Irene Mannering, et al.
The British Journal of Dermatology|April 28, 2022
Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitisVivian Laquer, Viviana Parra, Jean-Philippe Lacour, et al.
Dermatology and Therapy|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb TrialNada Elbuluk, April W Armstrong, Ronald Vender, et al.
The Journal of Allergy and Clinical Immunology|November 13, 2025
Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study resultsDiamant Thaçi, Vivian Laquer, Charles Lynde, et al.
Journal of the American Academy of Dermatology|May 25, 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, et al.
International Journal of Dermatology|April 29, 2024
Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentationAndrew Alexis, James Q Del Rosso, Seth Forman, et al.
Pageof 3